Mitsubishi UFJ Asset Management Co. Ltd. Has $16.80 Million Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 16.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,002,472 shares of the company’s stock after purchasing an additional 141,143 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.09% of Teva Pharmaceutical Industries worth $16,801,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. New Age Alpha Advisors LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 1st quarter valued at about $43,000. Sound Income Strategies LLC boosted its position in Teva Pharmaceutical Industries by 3,715.8% during the second quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock worth $49,000 after purchasing an additional 2,824 shares during the period. Banque Cantonale Vaudoise acquired a new position in Teva Pharmaceutical Industries during the first quarter valued at approximately $74,000. CWM LLC raised its position in shares of Teva Pharmaceutical Industries by 18.1% in the second quarter. CWM LLC now owns 4,995 shares of the company’s stock valued at $84,000 after purchasing an additional 767 shares during the period. Finally, Brooklyn Investment Group lifted its stake in shares of Teva Pharmaceutical Industries by 403.4% in the first quarter. Brooklyn Investment Group now owns 5,009 shares of the company’s stock worth $77,000 after buying an additional 4,014 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on TEVA. UBS Group boosted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. JPMorgan Chase & Co. boosted their price objective on Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 8th. Finally, Wall Street Zen upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 11th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $25.86.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 200,000 shares of the business’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $24.11, for a total value of $4,822,000.00. Following the sale, the director owned 495,000 shares of the company’s stock, valued at $11,934,450. The trade was a 28.78% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.55% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Trading Up 3.5%

Shares of TEVA opened at $25.11 on Wednesday. The stock’s 50-day moving average price is $19.98 and its 200 day moving average price is $18.03. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45. The firm has a market capitalization of $28.80 billion, a price-to-earnings ratio of -156.94, a P/E/G ratio of 1.11 and a beta of 0.70. Teva Pharmaceutical Industries Ltd. has a 12-month low of $12.47 and a 12-month high of $25.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.10. The company had revenue of $4.48 billion during the quarter, compared to the consensus estimate of $4.36 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The company’s quarterly revenue was up 3.4% on a year-over-year basis. During the same quarter last year, the company earned $0.69 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.550-2.650 EPS. As a group, research analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.